Muenchbach Martin 4
4 · Radius Health, Inc. · Filed May 19, 2011
Insider Transaction Report
Form 4
Muenchbach Martin
Director
Transactions
- Award
Series A-2 Convertible Preferred Stock
2011-05-17+105,162→ 105,162 total(indirect: By Fund)From: 2011-05-17→ Common Stock (1,051,620 underlying) - Award
Series A-1 Convertible Preferred Stock
2011-05-17+43,596→ 43,596 total(indirect: By Fund)From: 2011-05-17→ Common Stock (435,960 underlying)
Footnotes (5)
- [F1]The Series A-1 convertible preferred stock is convertible into common stock at any time on a one-for-ten basis, and has no expiration date.
- [F2]Received in exchange for 435,960 shares of common stock of Radius Health, Inc. in connection with the merger of RHI Merger Corp., a wholly-owned subsidiary of the Registrant (f/k/a MPM Acquisition Corp.), with and into Radius Health, Inc. ("Target") pursuant to which Target survived and became a wholly-owned subsidiary of Registrant (the "Surviving Corporation"). Following such merger, the Surviving Corporation merged with and into its parent corporation, the Registrant, and subsequently changed its name to "Radius Health, Inc." (the "Merger").
- [F3]The reported securities are owned directly by BB Biotech Ventures II. Voting and investment power with respect to these shares is shared by the general partners of this fund. Dr. Muenchbach disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
- [F4]The Series A-2 convertible preferred stock is convertible into common stock at any time on a one-for-ten basis, and has no expiration date.
- [F5]Received in exchange for 1,051,620 shares of Series A-2 convertible preferred stock of Radius Health, Inc. in connection with the Merger.